` GMAB (Genmab A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

GMAB
vs
OMX Copenhagen 25

Over the past 12 months, GMAB has underperformed OMX Copenhagen 25, delivering a return of -31% compared to the OMX Copenhagen 25's 8% drop.

Stocks Performance
GMAB vs OMX Copenhagen 25

Loading
GMAB
OMX Copenhagen 25
Add Stock

Performance Gap
GMAB vs OMX Copenhagen 25

Loading
GMAB
OMX Copenhagen 25
Difference

Performance By Year
GMAB vs OMX Copenhagen 25

Loading
GMAB
OMX Copenhagen 25
Add Stock

Competitors Performance
Genmab A/S vs Peers

OMX Copenhagen 25
GMAB
ABBV
AMGN
GILD
VRTX
Add Stock

Genmab A/S
Glance View

Economic Moat
Narrow
Market Cap
88.9B DKK
Industry
Biotechnology

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
2 551.82 DKK
Undervaluation 45%
Intrinsic Value
Price
Back to Top